Last reviewed · How we verify

ranibizumab, aflibercept, pegaptanib, verteporphin

Kagawa University · FDA-approved active Small molecule Quality 2/100

ranibizumab, aflibercept, pegaptanib, verteporphin is a Small molecule drug developed by Kagawa University. It is currently FDA-approved. Also known as: Lucentis, Eylea, Macugen, Vizudyne.

At a glance

Generic nameranibizumab, aflibercept, pegaptanib, verteporphin
Also known asLucentis, Eylea, Macugen, Vizudyne
SponsorKagawa University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ranibizumab, aflibercept, pegaptanib, verteporphin

What is ranibizumab, aflibercept, pegaptanib, verteporphin?

ranibizumab, aflibercept, pegaptanib, verteporphin is a Small molecule drug developed by Kagawa University.

Who makes ranibizumab, aflibercept, pegaptanib, verteporphin?

ranibizumab, aflibercept, pegaptanib, verteporphin is developed and marketed by Kagawa University (see full Kagawa University pipeline at /company/kagawa-university).

Is ranibizumab, aflibercept, pegaptanib, verteporphin also known as anything else?

ranibizumab, aflibercept, pegaptanib, verteporphin is also known as Lucentis, Eylea, Macugen, Vizudyne.

What development phase is ranibizumab, aflibercept, pegaptanib, verteporphin in?

ranibizumab, aflibercept, pegaptanib, verteporphin is FDA-approved (marketed).

Related